 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Oral Selinexor for the treatment of recurrent glioblastoma

Clin Cancer Res: Oral Selinexor for the treatment of recurrent glioblastoma

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

eagle safety cans

levium side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Selinexor is an oral selective exportin-1 inhibitor (XPO1).
It is the world’s first selective nuclear export (SINE) inhibitor for the treatment of multiple myeloma (MM).
Created by Karyopharm Therapeutics, it is effective for various solid and hematological tumors
.

This study evaluated the penetrability, safety and effectiveness of selinexor as a single agent in the treatment of recurrent glioblastoma
.

76 adult patients with recurrent glioblastoma with Karnofsky performance status ≥ 60 points were recruited
.

Patients undergoing cytoreductive surgery will receive up to three doses of selinexor before surgery (group A, n=8, 2 times/week)

Progression-free survival rate of each group

The median concentration of selinexor in resected tumors in patients who received selinexor treatment before surgery was 105.
4 nM (range 39.
7-291 nM)
.

In groups B, C, and D, the 6-month progression-free survival rates were 10% (95% CI 2.

In group B, group C, and group D, the 6-month progression-free survival rate was 10% (95%CI 2.

Overall survival rate of each group

Serious side effects (AE) occurred in 26% (34%) of patients, one of which was fatal (1.
3%)
.

The most common treatment-related side effects are fatigue (61%), nausea (59%), decreased appetite (43%) and thrombocytopenia (43%); but after supporting symptomatic treatment and dose adjustment, most of the side effects are Controllable

In summary, for adult patients with recurrent glioblastoma, a single dose of 80 mg selinexor per week can induce remission, improve the patient's clinical relative progression-free survival rate, and control the side effects
.

For adult patients with recurrent glioblastoma, a single dose of 80 mg selinexor per week can induce remission, improve the patient's clinical relative progression-free survival rate, and controllable side effects
.

Original source:

Lassman Andrew B,Wen Patrick Y,van den Bent Martin J et al.

Phase 2 Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.